Zusammenfassung
Eine alkoholische (AFL) und eine nicht alkoholische Fettleber (NAFL) zeichnen sich durch eine Einlagerung von Lipiden in die Hepatozyten aus. Bei einer Beteiligung von > 5 % der Hepatozyten spricht man von „Verfettung”, bei > 50 % von einer „Fettleber”. Eine zusätzliche Entzündungsreaktion mit hepatozytärer Ballonierung führt zur alkoholischen (ASH) oder nicht alkoholischen (NASH) Steatohepatitis. Eine ASH bzw. NASH kann zur Fibrose oder Zirrhose führen. In der klinischen Praxis ist es bislang allein auf Basis nicht invasiver Tests nicht möglich, zwischen Steatose und Steatohepatitis zu unterscheiden. Eine Steatohepatitis liegt dann vor, wenn neben der Steatose gemischtzellige entzündliche Infiltrate in den Leberläppchen nachweisbar sind und zusätzlich eine Leberzellschädigung in Form einer Ballonierung vorliegt. Die Leberbiopsie ist der „Goldstandard” bei der Sicherung der Diagnose sowie der Bestimmung der entzündlichen Aktivität und möglichen Fibrose einer Fettlebererkrankung. Die Indikation zur Biopsie sollte den möglichen Informationsgewinn durch die Biopsie und seine Konsequenzen im Vergleich zu Aufwand und Komplikationsrate berücksichtigen und daher im klinischen Kontext gestellt werden.
Abstract
Alcoholic fatty liver (AFL) as well as non-alcoholic fatty liver (NAFL) are characterised by deposition of lipids into hepatocytes. The diagnosis of steatosis is made if lipid deposition exceeds 5 % of hepatocytes, in case of more than 50 % it is called ”fatty liver”. An additional inflammatory reaction, with ballooning of hepatocytes, leads to alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH). Both ASH or NASH may lead to fibrosis or cirrhosis. To date in clinical practice it is not possible to differentiate between steatosis and steatohepatitis just on the basis of non-invasive tests. Steatohepatitis is present if, along with steatosis, both inflammatory infiltrates of mixed cells in the small liver lobules and liver cell injury in terms of ballooning can be detected. Liver biopsy represents the ”gold standard” for confirming the diagnosis and to determine inflammatory activity and potential fibrosis of fatty liver disease. Indications for biopsy should take into account the possible information and its consequences as compared to expense and complication rate and therefore should be assessed in the clinical context.
Schlüsselwörter
nicht alkoholische Steatohepatitis - alkoholische Steatohepatitis - Chemotherapie - kindliche NASH - Ballonierung - Fibrose - Zirrhose - Differenzialdiagnose - Scoring - Leberbiopsie
Key words
non-alcoholic steatohepatitis - alcoholic steatohepatitis - chemotherapy - NASH in children - ballooning - fibrosis - cirrhosis - differential diagnosis - scoring - liver biopsy
Literatur
1
Adams L A, Talwalkar J A.
Diagnostic evaluation of nonalcoholic fatty liver disease.
J Clin Gastroenterol.
2006;
40
34-38
2
AGA .
American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease.
Gastroenterology.
2002;
123
1702-1704
3
Alfire M E, Treem W R.
Nonalcoholic fatty liver disease.
Pediatr Ann.
2006;
35
290-299
4
Aloia T, Sebagh M, Plasse M. et al .
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
J Clin Oncol.
2006;
24
4983-4990
5
Angulo P, Hui J M, Marchesini G. et al .
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Hepatology.
2007;
45
846-854
6
Angulo P, Lindor K D.
Non-alcoholic fatty liver disease.
J Gastroenterol Hepatol.
2002;
17
S186-S190
7
Bacon B R, Farahvash M J, Janney C G. et al .
Nonalcoholic steatohepatitis: an expanded clinical entity.
Gastroenterology.
1994;
107
1103-1109
8
Baumann U.
Die kindliche Fettlebererkrankung.
Dtsch Ärzteblatt.
2005;
102
A2634-A2639
9
Bellentani S, Bedogni G, Miglioli L. et al .
The epidemiology of fatty liver.
Eur J Gastroenterol Hepatol.
2004;
16
1087-1093
10
Bonekamp S, Kamel I, Solga S. et al .
Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?.
J Hepatol.
2009;
50
17-35
11
Brunt E M.
Nonalcoholic steatohepatitis: definition and pathology.
Semin Liver Dis.
2001;
21
3-16
12
Brunt E M.
Alcoholic and nonalcoholic steatohepatitis.
Clin Liver Dis.
2002;
6
399-420
13
Brunt E M.
Pathology of fatty liver disease.
Mod Pathol.
2007;
20
S40-S48
(S 01)
14
Brunt E M.
Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.
Semin Diagn Pathol.
2005;
22
330-338
15
Brunt E M.
Pathology of nonalcoholic steatohepatitis.
Hepatol Res.
2005;
33
68-71
16
Brunt E M, Janney C G, Di Bisceglie A M. et al .
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.
Am J Gastroenterol.
1999;
94
2467-2474
17
Brunt E M, Neuschwander-Tetri B A, Oliver D. et al .
Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
Hum Pathol.
2004;
35
1070-1082
18
Brunt E M, Ramrakhiani S, Cordes B G. et al .
Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.
Mod Pathol.
2003;
16
49-56
19
Brunt E M, Tiniakos D G.
Pathology of steatohepatitis.
Best Pract Res Clin Gastroenterol.
2002;
16
691-707
20
Brunt E M, Tiniakos D G.
Pathological features of NASH.
Front Biosci.
2005;
10
1475-1484
21
Burt A D, Mutton A, Day C P.
Diagnosis and interpretation of steatosis and steatohepatitis.
Semin Diagn Pathol.
1998;
15
246-258
22
Caldwell S H, Oelsner D H, Iezzoni J C. et al .
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.
Hepatology.
1999;
29
664-669
23
Castera L, Forns X, Alberti A.
Non-invasive evaluation of liver fibrosis using transient elastography.
J Hepatol.
2008;
48
835-847
24
Chitturi S, Abeygunasekera S, Farrell G C. et al .
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.
Hepatology.
2002;
35
373-379
25
Church T S, Kuk J L, Ross R. et al .
Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease.
Gastroenterology.
2006;
130
2023-2030
26
Cortez-Pinto H, Moura M C, Day C P.
Non-alcoholic steatohepatitis: from cell biology to clinical practice.
J Hepatol.
2006;
44
197-208
27
Dancygier de H.
Pathogenese und Therapie der nichtalkoholischen Fettlebererkrankungen.
Dtsch Ärzteblatt.
2006;
103
A1301-A1307
28
Day C P.
Non-alcoholic fatty liver disease: current concepts and management strategies.
Clin Med.
2006;
6
19-25
29
Day C P.
Pathogenesis of steatohepatitis.
Best Pract Res Clin Gastroenterol.
2002;
16
663-678
30
Day C P, James O F.
Steatohepatitis: a tale of two ”hits”?.
Gastroenterology.
1998;
114
842-845
31
DeLeve L D, Shulman H M, McDonald G B.
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).
Semin Liver Dis.
2002;
22
27-42
32
Dufour J F, Oneta C M.
Alcoholic and non-alcoholic steatohepatitis.
Ther Umsch.
2004;
61
505-512
33
Duvnjak M, Lerotic I, Barsic N. et al .
Pathogenesis and management issues for non-alcoholic fatty liver disease.
World J Gastroenterol.
2007;
13
4539-4550
34
Edmison J, McCullough A J.
Pathogenesis of non-alcoholic steatohepatitis: human data.
Clin Liver Dis.
2007;
11
75-104
35
Falck-Ytter Y, Younossi Z M, Marchesini G. et al .
Clinical features and natural history of nonalcoholic steatosis syndromes.
Semin Liver Dis.
2001;
21
17-26
36
Farrell G C, Larter C Z.
Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
Hepatology.
2006;
43
S99-S112
37
Friedrich-Rust M, Ong M F, Martens S. et al .
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.
Gastroenterology.
2008;
134
960-974
38
Gentilucci U V, Santini D, Vincenzi B. et al .
Chemotherapy-induced steatohepatitis in colorectal cancer patients.
J Clin Oncol.
2006;
24
5467-5468
39
Gramlich T, Kleiner D E, McCullough A J. et al .
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.
Hum Pathol.
2004;
35
196-199
40
Harrison S A, Torgerson S, Hayashi P H.
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study.
Am J Gastroenterol.
2003;
98
2042-2047
41
Hubscher S G.
Role of liver biopsy in the assessment of non-alcoholic fatty liver disease.
Eur J Gastroenterol Hepatol.
2004;
16
1107-1115
42
Joy D, Thava V R, Scott B B.
Diagnosis of fatty liver disease: is biopsy necessary?.
Eur J Gastroenterol Hepatol.
2003;
15
539-543
43
Kacerovsky M, Roden M.
Nichtalkoholische Fettleber.
Diabetologe.
2007;
3
176-183
44
Karoui M, Penna C, min-Hashem M. et al .
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.
Ann Surg.
2006;
243
1-7
45
Kleiner D E, Brunt E M, Van Natta M. et al .
Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
Hepatology.
2005;
41
1313-1321
46
Lackner C, Gogg-Kamerer M, Zatloukal K. et al .
Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis.
J Hepatol.
2008;
48
821-828
47
Ludwig J, McGill D B, Lindor K D.
Review: nonalcoholic steatohepatitis.
J Gastroenterol Hepatol.
1997;
12
398-403
48
Ludwig J, Viggiano T R, McGill D B. et al .
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
Mayo Clin Proc.
1980;
55
434-438
49
Matteoni C A, Younossi Z M, Gramlich T. et al .
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Gastroenterology.
1999;
116
1413-1419
50
Medina J, Fernandez-Salazar L I, Garcia-Buey L. et al .
Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.
Diabetes Care.
2004;
27
2057-2066
51
Mendez-Sanchez N, Arrese M, Zamora-Valdes D. et al .
Current concepts in the pathogenesis of nonalcoholic fatty liver disease.
Liver Int.
2007;
27
423-433
52
Mendler M H, Kanel G, Govindarajan S.
Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease.
Liver Int.
2005;
25
294-304
53
Mofrad P, Contos M J, Haque M. et al .
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.
Hepatology.
2003;
37
1286-1292
54
Moss A, Wabitsch M, Kromeyer-Hauschild K. et al .
Prevalence of overweight and adiposity in German school children.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz.
2007;
50
1424-1431
55
Nakano H, Oussoultzoglou E, Rosso E. et al .
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
Ann Surg.
2008;
247
118-124
56
Neuschwander-Tetri B A.
Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.
Curr Gastroenterol Rep.
2002;
4
31-36
57
Neuschwander-Tetri B A, Caldwell S H.
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.
Hepatology.
2003;
37
1202-1219
58
Nocito A, El-Badry A M, Clavien P A.
When is steatosis too much for transplantation?.
J Hepatol.
2006;
45
494-499
59
Nordlinger B, Van Cutsem E, Rougier P. et al .
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.
Eur J Cancer.
2007;
43
2037-2045
60
Oneta C M, Dufour J F.
Diagnostik, Prognose und therapeutische Möglichkeiten der nicht-alkoholischen Fettlebererkrankung.
Schweiz Med Forum.
2003;
37
862-868
61
Papandreou D, Rousso I, Mavromichalis I.
Update on non-alcoholic fatty liver disease in children.
Clin Nutr.
2007;
26
409-415
62
Rashid M, Roberts E.
Nonalcoholic steatohepatitis in children.
J Pediatr Gastroenterol Nutr.
2000;
30
48-53
63
Ratziu V, Charlotte F, Heurtier A. et al .
Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
Gastroenterology.
2005;
128
1898-1906
64
Reid A E.
Nonalcoholic steatohepatitis.
Gastroenterology.
2001;
121
710-723
65
Roberts E A.
Steatohepatitis in children.
Best Pract Res Clin Gastroenterol.
2002;
16
749-765
66
Roberts E A.
Non-alcoholic steatohepatitis in children.
Clin Liver Dis.
2007;
11
155-72
67
Rousselet M C, Michalak S, Dupre F. et al .
Sources of variability in histological scoring of chronic viral hepatitis.
Hepatology.
2005;
41
257-264
68
Sanyal A J, Banas C, Sargeant C. et al .
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.
Hepatology.
2006;
43
682-689
69
Schwimmer J B.
Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.
Semin Liver Dis.
2007;
27
312-318
70
Schwimmer J B, Behling C, Newbury R. et al .
Histopathology of pediatric nonalcoholic fatty liver disease.
Hepatology.
2005;
42
641-649
71
Sonsuz A, Basaranoglu M, Ozbay G.
Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis.
Am J Gastroenterol.
2000;
95
1370-1371
72
Strassburg C P, Manns M P.
Approaches to liver biopsy techniques – revisited.
Semin Liver Dis.
2006;
26
318-327
73
Tannapfel A, Geissler F, Witzigmann H. et al .
Analysis of liver allograft rejection related genes using cDNA-microarrays in liver allograft specimen.
Transplant Proc.
2001;
33
3283-3284
74
Tannapfel A, Reinacher-Schick A.
Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC).
Z Gastroenterol.
2008;
46
435-440
75
Targher G, Bertolini L, Rodella S. et al .
Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
Clin Endocrinol (Oxf).
2006;
64
679-683
76
Teli M R, James O F, Burt A D. et al .
The natural history of nonalcoholic fatty liver: a follow-up study.
Hepatology.
1995;
22
1714-1719
77
Vauthey J N, Pawlik T M, Ribero D.
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.
J Clin Oncol.
2006;
24
2065-2072
78
Wieckowska A, McCullough A J, Feldstein A E.
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
Hepatology.
2007;
46
582-589
79
Wieckowska A, Zein N N, Yerian L M. et al .
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
Hepatology.
2006;
44
27-33
80
Younossi Z M, Jarrar M, Nugent C. et al .
A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH).
Obes Surg.
2008;
18
1430-1437
81
Zivkovic A M, German J B, Sanyal A J.
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease.
Am J Clin Nutr.
2007;
86
285-300
Prof. Dr. Andrea Tannapfel
Institut für Pathologie, Ruhr-Universität Bochum
Bürkle-de-la-Camp Platz 1
44789 Bochum
Phone: ++ 49/2 34/3 02 48 00
Fax: ++ 49/2 34/3 02 48 09
Email: andrea.tannapfel@rub.de